MAPT and Alzheimer disease: For that reason, our results that rs9357347 exerted a significant effect on AD by modulating CSF biomarkers including Aβ1-42, T-tau, and P-tau 181 has thrown light on the hypothesis about the mechanism through which TREML1 modifies AD risk, which still needs further investigation.